Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01084330 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT01084330 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 68 participants.
The verdict
NCT01084330, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
A clinical trial to determine the effectiveness and safety of AUY922 compared to other drugs known to be effective against gastric cancer in second line therapy for patients who have failed one line of chemotherapy.
Interventions
- DRUG Docetaxel
- DRUG Irinotecan
- DRUG AUY922
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01084330
The ClinicalTrials.gov registry entry for NCT01084330 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT01084330 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01084330 about?
NCT01084330 is a clinical study titled "Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer". A clinical trial to determine the effectiveness and safety of AUY922 compared to other drugs known to be effective against gastric cancer in second line therapy for patients who have failed one line of chemotherapy.
What is the current status of trial NCT01084330?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2010-04. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01084330?
The interventions under investigation include: Docetaxel (DRUG), Irinotecan (DRUG), AUY922 (DRUG).
Who is sponsoring clinical trial NCT01084330?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.